Eton Pharmaceuticals, Inc. (ETON): M&A transaction — Eton acquires Galzin (zinc acetate) for $7.2M; rare disease product for Wilson Disease

Eton Pharmaceuticals, Inc.

Acquired Galzin from Teva Pharmaceuticals for $7.0M at closing plus $0.2M for inventory.
Will pay Teva a 10% royalty on U.S. net sales through the tenth anniversary of first commercial sale.
Galzin is the only FDA-approved zinc maintenance therapy for Wilson Disease; <5,000 U.S. patients.
Eton expects to assume U.S. commercialization in Q1 2025 with its metabolic sales force.
Also acquired European rights; third party commercializes under Wilzin with Eton supplying product.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Eton Pharmaceuticals, Inc. completed an acquisition involving Teva Pharmaceuticals USA, Inc. for $7.0 million at closing (closed 2024-12-31).

Action: acquisition
Counterparty: Teva Pharmaceuticals USA, Inc.
Consideration: $7.0 million at closing
Closing: 2024-12-31

Exact text from the filing

product to the third party and the third party is responsible for all commercialization activities. Under the terms of the purchase agreement, the Company purchased Galzin® for $7.0 million at closing and paid an additional $0.2 million for product inventory. The Company will also pay Teva a royalty of 10% of U.S. net sales through the tenth anniversary of the

View on SEC.gov

Browse all m&a transactions →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-000109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.